Abstract
Introduction
Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Proton magnetic resonance spectroscopy (1H-MRS) gives completely different information, relating to cell membrane proliferation, neuronal damage, energy metabolism and necrotic transformation of brain or tumor tissues. The aim of this study was to investigate the relationship between 1H-MRS and tumor proliferative potential in astrocytomas.
Methods
We studied 34 patients with histologically verified astrocytomas using the 1H-MRS protocol following routine MRI preoperatively. The tumor in 26 of these patients was classified as grade I/II (low grade), and the tumor in the remaining patients as grade III/IV (high grade) according to the World Health Organization classification criteria of nervous system tumors (2000). The tumor in 21 patients was homogeneous astrocytoma, and of these 17 were classified as low grade and 4 as high grade. Expression of proliferating cell nuclear antigen (PCNA) was determined immunohistochemically using streptavidin-biotin-peroxidase complex (SP) staining.
Results
The ratios of choline (Cho) to N-acetylaspartate (NAA) and Cho to creatine (Cr) in those with high-grade astrocytomas (n=4) were significantly higher than in those with low-grade astrocytomas (n=17) (t=2.899, P=0.009; t=3.96, P=0.001, respectively), and were found to be significantly correlated with the expression of PCNA in 21 patients with homogeneous astrocytomas (r=0.455, P=0.038; r=0.633, P=0.002, respectively).
Conclusions
We conclude that 1H-MRS may be a valuable method for predicting preoperatively the degree of malignancy of homogeneous astrocytomas by enabling the calculation of the Cho/NAA and Cho/Cr ratios in vivo, and indirect evaluation of the tumor proliferative potential and prognosis, which are not available using conventional magnetic resonance imaging (MRI).
Similar content being viewed by others
References
Wu JM, Cai XD, Fu YZ (2000) Research in the expression of proliferating cell nuclear antigen in the malignant progress of astrocytomas (in Chinese). Chin J Neurosurg 16:187–189
Chen CQ, Wang XY, Chen C (1999) The relative study between the manifestation in magnetic resonance imaging and the expression of proliferating cell nuclear antigen in supratentorial astrocytomas (in Chinese). Chin J Radiol 33:561–564
Magalhaes A, Godfrey W, Shen Yimin, Hu Jiani, Smith W (2005) Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol 12:51–57
Izumiyama H, Abe T, Tanioka D, Fukuda A, Kunii N (2004) Clinicopathological examination of glioma by proton magnetic resonance spectroscopy background. Brain Tumor Pathol 21:39–46
Möller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE (2002) Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44:371–381
Ott D, Hennig J, Ernst T (1993) Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 186:745–752
Cendes F, Leproux F, Melanson D, Ethier R, Evans A, Peters T, Andermann F (1993) MRI of amygdala and hippocampus in temporal lobe epilepsy. J Comput Asist Tomogr 17:206–210
Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G (1997) Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87:516–524
Fountas KN, Kapsalaki EZ, Vogel RL, Fezoulidis I, Robinson JS, Gotsis ED (2004) Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotact Funct Neurosurg 82:90–97
Yang D, Korogi Y, Sugahara T, Kitajima M, Shigematsu Y, Liang L, Ushio Y, Takahashi M (2002) Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44:656–666
Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M (2005) Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 18:371–382
Shimizu H, Kumabe T, Shirane R, Yoshimoto T (2000) Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 21:659–665
Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA, Friedmann G, Heiss WD (1990) Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 176:791–799
Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL (2003) Increased cell proliferation and neurogenesis in the adult human Huntington’s disease brain. Proc Natl Acad Sci U S A 100:9023–9027
Yue H, Na YL, Feng XL, Ma SR, Song FL, Yang B (2003) Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer. World J Gastroenterol 9:377–380
Bian XW, Shi JQ, Liu FX (2000) Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors. Anal Quant Cytol Histol 22:429–437
Kirkegaard LJ, DeRose PB, Yao B, Cohen C (1998) Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas, Prognostic significance. Am J Clin Pathol 109:69–74
Korkolopoulou P, Christodoulou P, Lekka-Katsouli I, Kouzelis K, Papanikolaou A, Panayotides I, Mariatos P, Thomas-Tsagli E, Crocker J (1994) Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology 25:349–355
Nafe R, Herminghaus S, Pilatus U, Hattingen E, Marquardt G, Schlote W, Lanfermann H, Zanella F (2004) Morphology of proliferating and non-proliferating tumor cell nuclei in glioblastomas correlates with preoperative data from proton-MR-spectroscopy. Neuropathology 24:172–182
Sharma M, Ralte A, Arora R, Santosh V, Shankar SK, Sarkar C (2004) Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins. Pathology 36:139–144
Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neurooncol 58:217–236
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J., Huang, SL., Li, T. et al. In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology 48, 312–318 (2006). https://doi.org/10.1007/s00234-006-0066-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00234-006-0066-3